For New Antipsychotic Users, Dose, Duration Impact Mortality

This article originally appeared here.
Share this content:
For New Antipsychotic Users, Dose, Duration Impact Mortality
For New Antipsychotic Users, Dose, Duration Impact Mortality

TUESDAY, May 17, 2016 (HealthDay News) -- Dose and duration of therapy are associated with mortality for new antipsychotic users, according to a study published online May 10 in the Journal of the American Geriatrics Society.

Linda Simoni-Wastila, Ph.D., from the University of Maryland in Baltimore, and colleagues conducted a retrospective cohort study of Medicare beneficiaries who had a Minimum Data Set 2.0 clinical assessment completed between 2007 and 2009. The authors identified three mutually exclusive cohorts of new antipsychotic users with evidence of severe mental illness (SMI; 5,621 participants); dementia with behavioral symptoms (dementia + behavior) without SMI (1,090 participants); or delirium without SMI or dementia + behavior (2,100 participants). The dose (modified standardized daily dose [mSDD]) and duration of therapy with antipsychotic were assessed monthly.

The researchers found that mortality risk was significantly lower for new antipsychotic users with a mSDD of ≤1 versus those with a mSDD >1 (hazard ratio [HR]SMI, 0.77; HRdementia + behavior, 0.52; and HRdelirium, 0.61, respectively). Significantly lower mortality was seen with longer duration of antipsychotic use (91 to 184 days for SMI and delirium) versus short duration of use (≤30 days for SMI; ≤7 days for delirium). In the SMI cohort, the interaction between dose and duration was statistically significant (P < 0.001).

"Prescribers should monitor antipsychotic dosage throughout the course of antipsychotic treatment and customize dose and duration regimens to an individual's indications," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »